Nxera sells APAC license to lupus drug to Viatris for $10M upfront
Nxera Pharma has sold the Asia-Pacific rights to its phase 3 autoimmune drug to Viatris for $10 million upfront.

Feb 23, 2025 0
Feb 23, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 27, 2025 0
Feb 27, 2025 0
Feb 27, 2025 0
Feb 27, 2025 0
Feb 26, 2025 0
Or register with email
Feb 9, 2025 0
Feb 10, 2025 0
Feb 11, 2025 0
Feb 9, 2025 0
Feb 21, 2025 0
Feb 13, 2025 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.